115 related articles for article (PubMed ID: 38430628)
1. Characterisation of the cell and molecular biological effect of peptide-based daunorubicin conjugates developed for targeting pancreatic adenocarcinoma (PANC-1) cell line.
Szász Z; Enyedi KN; Takács A; Fekete N; Mező G; Kőhidai L; Lajkó E
Biomed Pharmacother; 2024 Apr; 173():116293. PubMed ID: 38430628
[TBL] [Abstract][Full Text] [Related]
2. Drug targeting to decrease cardiotoxicity - determination of the cytotoxic effect of GnRH-based conjugates containing doxorubicin, daunorubicin and methotrexate on human cardiomyocytes and endothelial cells.
Polgár L; Lajkó E; Soós P; Láng O; Manea M; Merkely B; Mező G; Kőhidai L
Beilstein J Org Chem; 2018; 14():1583-1594. PubMed ID: 30013686
[No Abstract] [Full Text] [Related]
3. Sequence modification of heptapeptide selected by phage display as homing device for HT-29 colon cancer cells to improve the anti-tumour activity of drug delivery systems.
Kiss K; Biri-Kovács B; Szabó R; Ranđelović I; Enyedi KN; Schlosser G; Orosz Á; Kapuvári B; Tóvári J; Mező G
Eur J Med Chem; 2019 Aug; 176():105-116. PubMed ID: 31100648
[TBL] [Abstract][Full Text] [Related]
4. Phage Display-Based Homing Peptide-Daunomycin Conjugates for Selective Drug Targeting to PANC-1 Pancreatic Cancer.
Dókus LE; Lajkó E; Ranđelović I; Mező D; Schlosser G; Kőhidai L; Tóvári J; Mező G
Pharmaceutics; 2020 Jun; 12(6):. PubMed ID: 32580307
[TBL] [Abstract][Full Text] [Related]
5. Comparative cell biological study of in vitro antitumor and antimetastatic activity on melanoma cells of GnRH-III-containing conjugates modified with short-chain fatty acids.
Lajkó E; Spring S; Hegedüs R; Biri-Kovács B; Ingebrandt S; Mező G; Kőhidai L
Beilstein J Org Chem; 2018; 14():2495-2509. PubMed ID: 30344773
[No Abstract] [Full Text] [Related]
6. Improved In Vivo Anti-Tumor and Anti-Metastatic Effect of GnRH-III-Daunorubicin Analogs on Colorectal and Breast Carcinoma Bearing Mice.
Ranđelović I; Schuster S; Kapuvári B; Fossati G; Steinkühler C; Mező G; Tóvári J
Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31557968
[TBL] [Abstract][Full Text] [Related]
7. In-vivo antitumour effect of daunorubicin-GnRH-III derivative conjugates on colon carcinoma-bearing mice.
Manea M; Tóvári J; Tejeda M; Schulcz A; Kapuvári B; Vincze B; Mezo G
Anticancer Drugs; 2012 Jan; 23(1):90-7. PubMed ID: 21915040
[TBL] [Abstract][Full Text] [Related]
8. A new daunomycin-peptide conjugate: synthesis, characterization and the effect on the protein expression profile of HL-60 cells in vitro.
Orbán E; Manea M; Marquadt A; Bánóczi Z; Csík G; Fellinger E; Bosze S; Hudecz F
Bioconjug Chem; 2011 Oct; 22(10):2154-65. PubMed ID: 21950465
[TBL] [Abstract][Full Text] [Related]
9. In Vivo Tumor Growth Inhibition and Antiangiogenic Effect of Cyclic NGR Peptide-Daunorubicin Conjugates Developed for Targeted Drug Delivery.
Tripodi AAP; Ranđelović I; Biri-Kovács B; Szeder B; Mező G; Tóvári J
Pathol Oncol Res; 2020 Jul; 26(3):1879-1892. PubMed ID: 31820302
[TBL] [Abstract][Full Text] [Related]
10. New daunomycin-oligoarginine conjugates: synthesis, characterization, and effect on human leukemia and human hepatoma cells.
Miklán Z; Orbán E; Csík G; Schlosser G; Magyar A; Hudecz F
Biopolymers; 2009; 92(6):489-501. PubMed ID: 19521976
[TBL] [Abstract][Full Text] [Related]
11. Oxime bond-linked daunorubicin-GnRH-III bioconjugates exert antitumor activity in castration-resistant prostate cancer cells via the type I GnRH receptor.
Montagnani Marelli M; Manea M; Moretti RM; Marzagalli M; Limonta P
Int J Oncol; 2015 Jan; 46(1):243-53. PubMed ID: 25351635
[TBL] [Abstract][Full Text] [Related]
12. Among substituted 9,10-dihydro-9,10-[1,2]benzenoanthracene-1,4,5,8-tetraones, the lead antitumor triptycene bisquinone TT24 blocks nucleoside transport, induces apoptotic DNA fragmentation and decreases the viability of L1210 leukemic cells in the nanomolar range of daunorubicin in vitro.
Perchellet EM; Sperfslage BJ; Wang Y; Huang X; Tamura M; Hua DH; Perchellet JP
Anticancer Drugs; 2002 Jul; 13(6):567-81. PubMed ID: 12172502
[TBL] [Abstract][Full Text] [Related]
13. Apoptotic Effects of Drug Targeting Conjugates Containing Different GnRH Analogs on Colon Carcinoma Cells.
Lajkó E; Hegedüs R; Mező G; Kőhidai L
Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31500399
[TBL] [Abstract][Full Text] [Related]
14. Improved in vivo antitumor effect of a daunorubicin - GnRH-III bioconjugate modified by apoptosis inducing agent butyric acid on colorectal carcinoma bearing mice.
Kapuvári B; Hegedüs R; Schulcz Á; Manea M; Tóvári J; Gacs A; Vincze B; Mező G
Invest New Drugs; 2016 Aug; 34(4):416-23. PubMed ID: 27146514
[TBL] [Abstract][Full Text] [Related]
15. [Comparison of therapeutic peptides targeting pancreatic cancer].
Mezõ G; Dókus L; Schlosser G; Lajkó E; Szász Z; Ranđelović I; Biri-Kovács B; Tóvári J; Kõhidai L
Magy Onkol; 2019 Dec; 63(4):301-308. PubMed ID: 31821385
[TBL] [Abstract][Full Text] [Related]
16. A synthetic triptycene bisquinone, which blocks nucleoside transport and induces DNA fragmentation, retains its cytotoxic efficacy in daunorubicin-resistant HL-60 cell lines.
Wang B; Wu M; Perchellet EM; McIlvain CJ; Sperfslage BJ; Huang X; Tamura M; Stephany HA; Hua DH; Perchellet JP
Int J Oncol; 2001 Dec; 19(6):1169-78. PubMed ID: 11713586
[TBL] [Abstract][Full Text] [Related]
17. Synthetic 1,4-anthracenediones, which block nucleoside transport and induce DNA fragmentation, retain their cytotoxic efficacy in daunorubicin-resistant HL-60 cell lines.
Wu M; Wang B; Perchellet EM; Sperfslage BJ; Stephany HA; Hua DH; Perchellet JP
Anticancer Drugs; 2001 Nov; 12(10):807-19. PubMed ID: 11707648
[TBL] [Abstract][Full Text] [Related]
18. Double targeting, controlled release and reversible delivery of daunorubicin to cancer cells by polyvalent aptamers-modified gold nanoparticles.
Taghdisi SM; Danesh NM; Lavaee P; Emrani AS; Hassanabad KY; Ramezani M; Abnous K
Mater Sci Eng C Mater Biol Appl; 2016 Apr; 61():753-61. PubMed ID: 26838906
[TBL] [Abstract][Full Text] [Related]
19. Novel peptide conjugates for tumor-specific chemotherapy.
Langer M; Kratz F; Rothen-Rutishauser B; Wunderli-Allenspach H; Beck-Sickinger AG
J Med Chem; 2001 Apr; 44(9):1341-8. PubMed ID: 11311056
[TBL] [Abstract][Full Text] [Related]
20. Development and Biochemical Characterization of Self-Immolative Linker Containing GnRH-III-Drug Conjugates.
Schuster S; Juhász É; Halmos G; Neundorf I; Gennari C; Mező G
Int J Mol Sci; 2022 May; 23(9):. PubMed ID: 35563462
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
